1,271 results match your criteria Prostate Cancer - Management of Localized Disease


Neoadjuvant Hormonal Therapy for Prostate Cancer: Morphologic Features and Predictive Parameters of Therapy Response.

Adv Anat Pathol 2022 Jul 13;29(4):252-258. Epub 2022 Apr 13.

The Key Laboratory of Experimental Teratology, Ministry of Education and Department of Pathology, Shandong University QiLu Medical College, School of Basic Medical Sciences.

The primary goals of neoadjuvant hormonal therapy (NHT) in prostate cancer (PCa) are to reduce the size of the tumor, lower positive surgical margin rate, attempt to reach pathologic remission, and improve survival. Although NHT has not been recommended by the National Comprehensive Cancer Network as a primary treatment option for patients with localized PCa, NHT is increasingly used in clinical trials for locally advanced PCa. More importantly, with the development of novel androgen signaling inhibitors, such as abiraterone and enzalutamide, there has been renewed interests in revisiting the role of such treatment in the neoadjuvant setting. Read More

View Article and Full-Text PDF

Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer.

Front Oncol 2022 20;12:863472. Epub 2022 May 20.

Department of Medical Cell BioPhysics, Faculty of Science and Technology, Technical Medical Center, University of Twente, Enschede, Netherlands.

Prostate cancer is the most dominant male malignancy worldwide. The clinical presentation of prostate cancer ranges from localized indolent to rapidly progressing lethal metastatic disease. Despite a decline in death rate over the past years, with the advent of early diagnosis and new treatment options, challenges remain towards the management of metastatic prostate cancer, particularly metastatic castration sensitive prostate cancer (mCSPC) and castration resistant prostate cancer (mCRPC). Read More

View Article and Full-Text PDF

Salvage Prostate Stereotactic Body Radiation Therapy After Definitive Cryoablation.

Adv Radiat Oncol 2022 May-Jun;7(3):100849. Epub 2021 Nov 13.

Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital-Long Island, Mineola, New York.

Purpose: Whole gland cryoablation is a guideline-approved definitive treatment for localized prostate cancer, and is being explored for partial gland ablation. However, there is limited data regarding management of cryoablation failures. Stereotactic body radiation therapy (SBRT) is a well-established method of primary treatment for prostate cancer. Read More

View Article and Full-Text PDF
November 2021

Enrichment of "Cribriform" morphologies (intraductal and cribriform adenocarcinoma) and genomic alterations in radiorecurrent prostate cancer.

Mod Pathol 2022 May 23. Epub 2022 May 23.

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Locally relapsed prostate cancer (PCa) after radiation therapy (RT) is associated with substantial morbidity and mortality. Morphological and molecular consequences that may contribute to RT resistance and local recurrence remain poorly understood. Locally recurrent PCa tissue from 53 patients with clinically localized PCa who failed with primary RT and subsequently underwent salvage radical prostatectomy (RP) was analyzed for tumor focality, clinicopathological, molecular, and genomic characteristics. Read More

View Article and Full-Text PDF

Irradiation of localized prostate cancer in the elderly: A systematic literature review.

Clin Transl Radiat Oncol 2022 Jul 20;35:1-8. Epub 2022 Apr 20.

Department of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Côte d'Azur, 33 avenue Valombrose, 06189 Nice Cedex 2, Nice, France.

Purpose: To analyze the literature that addresses radiation therapy for intermediate and high-risk prostate cancer (PC) in the elderly.

Patients And Methods: A PubMed literature search was conducted including articles from 01/01/2000 to 30/06/21, with the following keywords: PC, radiotherapy/brachytherapy and elderly. The analysis mainly focused on the issue of under-treatment in the elderly and the benefit/risk balance of irradiation. Read More

View Article and Full-Text PDF

Eccrine Carcinoma With an Unknown Primary: Managing Occult Cancer Through Multidisciplinary Tumor Board Collaboration.

Cureus 2022 Mar 15;14(3):e23183. Epub 2022 Mar 15.

Radiation Oncology, Mount Auburn Hospital, Harvard Medical School, Cambridge, USA.

Eccrine carcinomas are rare cutaneous cancers that tend to be locally aggressive. Here we report a rare case of a mucinous eccrine carcinoma presenting in axillary lymph nodes without an identifiable primary lesion. This is a 69-year-old male with a past medical history of benign prostatic hyperplasia, melanoma, basal cell carcinoma, hypercholesterolemia, hypertension, and arthritis who was found to have an elevated prostate-specific antigen. Read More

View Article and Full-Text PDF

Acute Toxicity of Ultrahypofractionation Compared With Moderate Hypofractionation in Prostate Cancer Treatment: A Randomized Trial.

Int J Radiat Oncol Biol Phys 2022 Apr 10. Epub 2022 Apr 10.

BC Cancer - Victoria, Victoria, British Columbia, Canada.

Purpose: We report on the early toxic effects and quality of life of localized prostate cancer radiation therapy in a randomized trial comparing moderate hypofractionation (MHF) with ultrahypofractionation (UHF).

Methods And Materials: We randomized patients with intermediate- to high-risk localized prostate cancer to radiation therapy with MHF (70 Gy in 28 daily fractions) or UHF (36.25 Gy in 5 weekly fractions). Read More

View Article and Full-Text PDF

Efficacy and toxicity following salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after radiotherapy.

Brachytherapy 2022 Mar 21. Epub 2022 Mar 21.

Radiotherapy Department, Gustave Roussy, Villejuif, France. Electronic address:

Introduction: The management of local relapse after prostate cancer radiotherapy is frequently based on androgen deprivation therapy. The aim of the study was to report Gustave Roussy's experience with salvage prostate brachytherapy.

Patients And Methods: All cases of localized prostate cancer presenting in an irradiated area who received salvage high dose rate (HDR) brachytherapy from 2013 to 2020 were retrospectively reviewed. Read More

View Article and Full-Text PDF

Implications of DNA damage repair alterations for the management of prostate cancer.

Curr Opin Urol 2022 05 9;32(3):302-310. Epub 2022 Mar 9.

Genitourinary Cancers Traslational Research Group, Institute of Biomedical Research in Malaga (IBIMA), Malaga.

Purpose Of Review: In this review, we summarize the prevalence of alterations in DNA damage repair (DDR) genes in prostate cancer, their clinical significance, the therapeutic strategies developed to take advantage of the impaired tumour ability to repair DNA and the diagnostic approaches available to identify patients likely to benefit from DDR-targeting agents.

Recent Findings: DDR alterations are more frequent in metastatic than in localized prostate cancer and some of them associate with aggressive disease whereas the significance of others remain unclear. The most appropriate management approach for DDR-defective prostate cancer patients is unknown. Read More

View Article and Full-Text PDF

Management of prostate cancer in older patients.

Jpn J Clin Oncol 2022 May;52(6):513-525

Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.

The incidence of prostate cancer among older men has increased in many countries, including Asian countries. However, older patients are ineligible for inclusion in large randomized trials, and the existing guidelines for the management of patients with prostate cancer do not provide specific treatment recommendations for older men. Therefore, generation of evidence for older patients with prostate cancer is a key imperative. Read More

View Article and Full-Text PDF

Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer.

J Urol 2022 07 25;208(1):80-89. Epub 2022 Feb 25.

Department of Urology, Stanford University, Stanford, California.

Purpose: Many localized prostate cancers will follow an indolent course. Management has shifted toward active surveillance (AS), yet an optimal regimen remains controversial especially regarding expensive multiparametric magnetic resonance imaging (MRI). We aimed to assess cost-effectiveness of MRI in AS protocols. Read More

View Article and Full-Text PDF

Comparison of Different Machine Learning Models in Prediction of Postirradiation Recurrence in Prostate Carcinoma Patients.

Biomed Res Int 2022 7;2022:7943609. Epub 2022 Feb 7.

Department of Nuclear Medicine, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.

After primary treatment of localized prostate carcinoma (PC), up to a third of patients have disease recurrence. Different predictive models have already been used either for initial stratification of PC patients or to predict disease recurrence. Recently, artificial intelligence has been introduced in the diagnosis and management of PC with a potential to revolutionize this field. Read More

View Article and Full-Text PDF

Protein signatures to distinguish aggressive from indolent prostate cancer.

Prostate 2022 04 31;82(5):605-616. Epub 2022 Jan 31.

Department of Radiology, Stanford University School of Medicine, Canary Center at Stanford for Cancer Early Detection, Palo Alto, California, USA.

Background: Distinguishing men with aggressive from indolent prostate cancer is critical to decisions in the management of clinically localized prostate cancer. Molecular signatures of aggressive disease could help men overcome this major clinical challenge by reducing unnecessary treatment and allowing more appropriate treatment of aggressive disease.

Methods: We performed a mass spectrometry-based proteomic analysis of normal and malignant prostate tissues from 22 men who underwent surgery for prostate cancer. Read More

View Article and Full-Text PDF

The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer.

Genome Med 2022 01 25;14(1). Epub 2022 Jan 25.

Department of Molecular Medicine (MOMA), Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus, Denmark.

Background: Circular RNAs (circRNAs) constitute a largely unexplored source for biomarker discovery in prostate cancer (PC). Here, we characterize the biomarker potential of circRNAs in PC, where the need for novel diagnostic and prognostic tools to facilitate more personalized management is pressing.

Methods: We profiled the transcriptomic landscape of circRNAs in PC by total RNA sequencing of 31 adjacent-normal and 143 tumor samples from localized (radical prostatectomy (RP)) and metastatic PC patients (cohort 1, training). Read More

View Article and Full-Text PDF
January 2022

Prognostic Genomic Tissue-Based Biomarkers in the Treatment of Localized Prostate Cancer.

J Pers Med 2022 Jan 7;12(1). Epub 2022 Jan 7.

Radiation Oncology Section, Department of Medicine and Surgery, Perugia General Hospital, University of Perugia, 06156 Perugia, Italy.

In localized prostate cancer clinicopathologic variables have been used to develop prognostic nomograms quantifying the probability of locally advanced disease, of pelvic lymph node and distant metastasis at diagnosis or the probability of recurrence after radical treatment of the primary tumor. These tools although essential in daily clinical practice for the management of such a heterogeneous disease, which can be cured with a wide spectrum of treatment strategies (i.e. Read More

View Article and Full-Text PDF
January 2022

Active surveillance for intermediate-risk prostate cancer.

World J Urol 2022 Jan 19;40(1):79-86. Epub 2022 Jan 19.

Department of Urology, Massachusetts General Hospital, 55 Fruit St, GRB 1100, Boston, MA, 02114, USA.

Introduction: Active surveillance (AS) is an established approach in the management of low-risk, localized prostate cancer. While the use of AS to manage intermediate-risk (IR) disease has gradually increased over time, there remains uncertainty with regards to its safety, with only a minority of IR patients currently being managed with this approach.

Materials And Methods: We conducted a narrative review based on an analysis of the literature focusing on articles describing AS for IR prostate cancer. Read More

View Article and Full-Text PDF
January 2022

Cancer statistics, 2022.

CA Cancer J Clin 2022 01 12;72(1):7-33. Epub 2022 Jan 12.

Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia.

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes. Incidence data (through 2018) were collected by the Surveillance, Epidemiology, and End Results program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2019) were collected by the National Center for Health Statistics. Read More

View Article and Full-Text PDF
January 2022

Functional Preservation and Oncologic Control following Robot-Assisted versus Laparoscopic Radical Prostatectomy for Intermediate- and High-Risk Localized Prostate Cancer: A Propensity Score Matched Analysis.

J Oncol 2021 21;2021:4375722. Epub 2021 Dec 21.

Department of Urology, The First Affiliated Hospital of Nanchang University, Yongwai Street 17, Nanchang, Jiangxi Province, China.

Aim: To evaluate the urinary continence (UC), erectile function, and cancer control obtained following robot-assisted radical prostatectomy (RARP) and laparoscopic radical prostatectomy (LRP) for intermediate- and high-risk localized prostate cancer (PCa).

Materials And Methods: 232 patients bearing intermediate- and high-risk localized PCa were enrolled in this study. Perioperative, functional, and oncological outcomes were analyzed after applying the propensity score matched method. Read More

View Article and Full-Text PDF
December 2021

An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.

Int J Radiat Oncol Biol Phys 2022 Jun 17;113(2):278-289. Epub 2021 Dec 17.

Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio. Electronic address:

Androgen deprivation therapy (ADT) is an integral component in the management of prostate cancer across multiple disease states. Traditionally, luteinizing hormone-releasing hormone (LHRH) agonists constituted the backbone of ADT. However, gonadotropin-releasing hormone receptor hormone (GnRH) antagonists also are available, which offer faster testosterone suppression and reduced likelihood of ADT-related adverse effects compared with LHRH agonists, including the potential for fewer ADT-associated major cardiac events. Read More

View Article and Full-Text PDF

Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer.

Value Health 2021 12 29;24(12):1737-1745. Epub 2021 Jul 29.

Cancer Health Services Research, Centre for Cancer Research, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia; Cancer Health Services Research, Centre for Health Policy, Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia; Department of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia.

Objectives: To estimate the lifetime health and economic outcomes of selecting active surveillance (AS), radical prostatectomy (RP), or radiation therapy (RT) as initial management for low- or favorable-risk localized prostate cancer.

Methods: A discrete-event simulation model was developed using evidence from published randomized trials. Health outcomes were measured in life-years and quality-adjusted life-years (QALYs). Read More

View Article and Full-Text PDF
December 2021

KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients.

Transl Androl Urol 2021 Oct;10(10):3946-3952

Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.

Background: The administration of docetaxel chemotherapy is one therapeutic option to delay disease progression and increase overall survival in metastatic castration resistant prostate cancer (mCRPC). However, about 15% of patients are primary resistant to chemotherapy and hence would benefit from an alternative mCRPC treatment. Despite intensive research, there are no robust clinical validated biomarkers to predict mCRPC therapy response. Read More

View Article and Full-Text PDF
October 2021

Communication between cells: exosomes as a delivery system in prostate cancer.

Cell Commun Signal 2021 11 12;19(1):110. Epub 2021 Nov 12.

Dipartimento di Medicina di Precisione, Università Della Campania 'L. Vanvitelli', Via L. De Crecchio, 7, 80138, Naples, Italy.

Despite the considerable efforts in screening and diagnostic protocols, prostate cancer still represents the second leading cause of cancer-related death in men. Many patients with localized disease and low risk of recurrence have a favourable outcome. In a substantial proportion of patients, however, the disease progresses and becomes aggressive. Read More

View Article and Full-Text PDF
November 2021

The impact of the extent and location of positive surgical margins on the risk of biochemical recurrence following radical prostatectomy in men with Gleason 7 prostate cancers.

Prostate 2021 12 27;81(16):1428-1434. Epub 2021 Sep 27.

Department of Surgery, The University of Auckland, Auckland, New Zealand.

Background: Positive surgical margins (PSM) after radical prostatectomy (RP) have been associated with increased risk of biochemical recurrence (BCR). This is heavily influenced by other clinicopathological factors. This study aims to assess the impact of the extent and location of PSM on BCR following RP for Gleason 7 carcinoma of the prostate (CaP). Read More

View Article and Full-Text PDF
December 2021

Utility of D2-40, Cytokeratin 5/6, and High-Molecular-weight Cytokeratin (Clone 34βE12) in Distinguishing Intraductal Spread of Urothelial Carcinoma From Prostatic Stromal Invasion.

Am J Surg Pathol 2022 04;46(4):454-463

Departments of Pathology and Laboratory Medicine.

Intraductal spread of urothelial carcinoma (UC) is not an uncommon finding in bladder cancer that requires appropriate clinical management. The presence of prostatic stromal invasion in non-muscle-invasive bladder cancer upstages the disease, necessitating cisplatin-based neoadjuvant chemotherapy and subsequent cystroprostatectomy. However, the identification of prostatic stromal invasion can be challenging, especially in biopsy and transurethral resection specimens. Read More

View Article and Full-Text PDF

Peritumoral Delivery of Docetaxel-TIPS Microparticles for Prostate Cancer Adjuvant Therapy.

Adv Ther (Weinh) 2021 Feb 19;4(2):2000179. Epub 2020 Oct 19.

Centre for Precision Healthcare UCL Division of Medicine University College London Gower Street London WC1E 6BT UK.

Recurrence of prostate cancer after radical prostatectomy is a consequence of incomplete tumor resection. Systemic chemotherapy after surgery is associated with significant toxicity. Improved delivery methods for toxic drugs capable of targeting positive resection margins can reduce tumor recurrence and avoid their known toxicity. Read More

View Article and Full-Text PDF
February 2021

Continuity of care in acute survivorship phase, and short and long-term outcomes in prostate cancer patients.

Prostate 2021 12 13;81(16):1310-1319. Epub 2021 Sep 13.

Division of Urology, Department of Surgery, Perelman School of Medicine, University of Pennsylvania.

Continuity of care is important for prostate cancer care due to multiple treatment options, and prolonged disease history. We examined the association between continuity of care and outcomes in Medicare beneficiaries with localized prostate cancer, and the moderating effect of race using Surveillance, Epidemiological, and End Results (SEER) - Medicare data between 2000 and 2016. Continuity of care was measured as visits dispersion (continuity of care index or COCI), and density (usual provider care index or UPCI) in acute survivorship phase. Read More

View Article and Full-Text PDF
December 2021

The Role of C-Reactive Protein in Kidney, Bladder, and Prostate Cancers.

Front Immunol 2021 27;12:721989. Epub 2021 Aug 27.

Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, United States.

C-Reactive Protein (CRP) is associated with diverse outcomes in patients with, or suspected to have, genitourinary malignancies. CRP levels have been shown to be associated with the probability of a prostate cancer diagnosis in patients with elevated PSA, the probability of biochemical recurrence following definitive treatment for localized prostate cancer, and decreased overall survival for patients with advanced disease. In patients with bladder and kidney cancers, CRP levels have been associated with disease progression, stage, and cancer-specific survival. Read More

View Article and Full-Text PDF
December 2021

Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trials.

Radiother Oncol 2021 10 4;163:159-164. Epub 2021 Sep 4.

Odette Cancer Centre, Sunnybrook Health Sciences Centre, Canada; Department of Radiation Oncology, University of Toronto, Canada; Institute of Health Policy, Management and Evaluation, Canada. Electronic address:

Background And Purpose: The role of elective nodal irradiation (ENI) in localized prostate cancer (PCa) is controversial. With increasing use of SBRT to the prostate, data is needed regarding the safety and efficacy of ENI using ultra-hypofractionated radiation (UHRT).

Materials And Methods: Between 2013-2020, 4 prospective clinical trials of intermediate or high-risk PCa receiving dose-escalated RT to the prostate (via HDR brachytherapy or SBRT boost) and ENI using UHRT (25 Gy in 5 weekly fractions) were conducted. Read More

View Article and Full-Text PDF
October 2021

Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial.

Int J Radiat Oncol Biol Phys 2022 02 1;112(2):294-303. Epub 2021 Sep 1.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Purpose: For men with localized prostate cancer, NRG Oncology/Radiation Therapy Oncology Group (RTOG) 9408 demonstrated that adding short-term androgen deprivation therapy (ADT) to radiation therapy (RT) improved the primary endpoint of overall survival (OS) and improved disease-specific mortality (DSM), biochemical failure (BF), local progression, and freedom from distant metastases (DM). This study was performed to determine whether the short-term ADT continued to improve OS, DSM, BF, and freedom from DM with longer follow-up.

Methods And Materials: From 1994 to 2001, NRG/RTOG 9408 randomized 2028 men from 212 North American institutions with T1b-T2b, N0 prostate adenocarcinoma and prostate-specific antigen (PSA) ≤20ng/mL to RT alone or RT plus short-term ADT. Read More

View Article and Full-Text PDF
February 2022

Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry.

Nat Rev Urol 2021 12 27;18(12):707-724. Epub 2021 Aug 27.

Department of Medical Biophysics, University of Toronto, Toronto, Canada.

Prostate cancer is the second most frequently diagnosed non-skin cancer in men worldwide. Patient outcomes are remarkably heterogeneous and the best existing clinical prognostic tools such as International Society of Urological Pathology Grade Group, pretreatment serum PSA concentration and T-category, do not accurately predict disease outcome for individual patients. Thus, patients newly diagnosed with prostate cancer are often overtreated or undertreated, reducing quality of life and increasing disease-specific mortality. Read More

View Article and Full-Text PDF
December 2021